ARAF复发突变导致对MEK抑制剂治疗有效的中央传导淋巴管异常
在1例12岁男孩和另1例无关成人患者中鉴定出复发性ARAF功能获得性突变(c.640T>C:p.S214P),该突变导致ERK1/2活性升高和淋巴管生成能力增强,斑马鱼模型重现淋巴表型且MEK抑制剂可逆转。先证者接受MEK抑制剂治疗后临床显著改善,淋巴系统重塑、淋巴水肿消退、肺功能改善、停止吸氧、日常活动接近正常。
要点
- ARAF c.640T>C:p.S214P复发突变见于对西罗莫司治疗无效的晚期淋巴管异常患者。
- 该突变导致ERK1/2活性升高、淋巴管生成能力增强及肌动蛋白骨架和VE-钙黏蛋白连接解体,MEK抑制剂曲美替尼可逆转。
- 先证者接受MEK抑制剂治疗后淋巴水肿消退、肺功能改善、停止补充氧气、日常活动接近正常。
核心结论
- ARAF复发功能获得性突变是中央传导淋巴管异常的致病原因,MEK抑制剂治疗可带来显著临床改善,作者称该治疗在本例中挽救了生命。
研究设计与样本
- 在1例12岁男孩(先证者)和另1例无关成人患者中鉴定ARAF突变,并进行细胞转导实验和斑马鱼模型功能验证。
主要发现
- 先证者为12岁男孩,患晚期异常淋巴疾病,对常规西罗莫司治疗无效,携带ARAF c.640T>C:p.S214P突变。
- 另一例无关成人患者也携带相同ARAF突变。
- 该突变导致保守磷酸化位点丢失。
- 转导ARAF-S214P的细胞显示ERK1/2活性升高、淋巴管生成能力增强、肌动蛋白骨架和VE-钙黏蛋白连接解体,使用MEK抑制剂曲美替尼可逆转这些改变。
- 斑马鱼模型重现淋巴表型,MEK抑制剂可逆转异常表型。
临床怎么用
- 先证者接受MEK抑制剂治疗后出现显著临床改善,淋巴系统重塑、淋巴水肿消退、肺功能检查明显改善、停止补充氧气需求、日常活动接近正常。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of lymphatic anomaly, a rare devastating disease spectrum of mostly unknown etiologies, depends on the patient manifestations1. Identifying the causal genes will allow for developing affordable therapies in keeping with precision medicine implementation2. Here we identified a recurrent gain-of-function ARAF mutation (c.640T>C:p.S214P) in a 12-year-old boy with advanced anomalous lymphatic disease unresponsive to conventional sirolimus therapy and in another, unrelated, adult patient. The mutation led to loss of a conserved phosphorylation site. Cells transduced with ARAF-S214P showed elevated ERK1/2 activity, enhanced lymphangiogenic capacity, and disassembly of actin skeleton and VE-cadherin junctions, which were rescued using the MEK inhibitor trametinib. The functional relevance of the mutation was also validated by recreating a lymphatic phenotype in a zebrafish model, with rescue of the anomalous phenotype using a MEK inhibitor. Subsequent therapy of the lead proband with a MEK inhibitor led to dramatic clinical improvement, with remodeling of the patient's lymphatic system with resolution of the lymphatic edema, marked improvement in his pulmonary function tests, cessation of supplemental oxygen requirements and near normalization of daily activities. Our results provide a representative demonstration of how knowledge of genetic classification and mechanistic understanding guides biologically based medical treatments, which in our instance was life-saving.
引用
- Li D, March ME, Gutierrez-Uzquiza A, et al. ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor. Nat Med. 2019. PMID: 31263281. doi:10.1038/s41591-019-0479-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。